Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas, Inc. develops targeted protein degradation medicines through its PROTAC protein degrader platform. Company updates center on VEPPANU (vepdegestrant), developed with Pfizer and approved by the FDA for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after endocrine-based therapy, as well as regulatory, clinical, and corporate milestones tied to that program.
Arvinas news also covers investigational PROTAC degraders across oncology, neurology, and neuromuscular disease, including ARV-102 for LRRK2-driven neurodegenerative disorders, ARV-806 for KRAS G12D-mutated cancers, ARV-393 for BCL6-driven lymphoma, and ARV-027 as a polyQ-AR degrader. Recurring items include clinical data presentations, financial results, corporate updates, investor conferences, and governance changes.
Summary not available.
Arvinas, Inc. (Nasdaq: ARVN) announced the appointment of Paul McInulty as Senior Vice President of Regulatory Affairs, effective October 3, 2022. McInulty brings over 25 years of biopharmaceutical experience, having previously held key roles at Bristol Myers Squibb and Celgene Corporation. His expertise will support Arvinas' transition into a late-stage development company focused on targeted protein degradation therapies. With a robust pipeline, including investigational programs for metastatic prostate and breast cancer, Arvinas aims to leverage McInulty’s experience to enhance regulatory strategies and overall growth trajectory.
On September 30, 2022, Arvinas, a clinical-stage biotechnology company, held its inaugural “Arvinas Impact Day,” with nearly 200 employees volunteering in the Greater New Haven area. The event emphasized community service, focusing on STEM initiatives and environmental protection. Highlights included educating over 300 students on financial literacy, enhancing facilities for a non-profit organization, and cleaning local beaches. CEO John Houston emphasized the company's commitment to community engagement and expressed enthusiasm for future initiatives.
Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, announced participation in a fireside chat at the Bank of America Securities Precision Oncology Conference on October 3, 2022, at 10:40 a.m. ET. The event will be accessible via a live audio webcast on Arvinas' website. The company is known for its innovative PROTAC® platform, which develops therapies aimed at degrading disease-causing proteins. Arvinas has several clinical-stage programs targeting prostate and breast cancers, reinforcing its commitment to advancing treatment options for severe diseases.
Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, announced its participation in three upcoming investor conferences in September 2022. The conferences include the Citi 17th Annual BioPharma Conference on September 8, the Wells Fargo Healthcare Conference on September 9, and the Morgan Stanley 20th Annual Global Healthcare Conference on September 12. Key executives will participate in fireside chats, with live webcasts available on their website. The company utilizes its proprietary PROTAC® technology to develop therapies for serious diseases.
Arvinas, Inc. (Nasdaq: ARVN) announced a board transition on August 18, 2022, with Liam Ratcliffe stepping down and John Young joining the Board of Directors. Ratcliffe, a significant contributor since 2015, was thanked by CEO John Houston for his guidance. Young, with nearly 35 years at Pfizer and experience in senior roles, is expected to contribute valuable insights as Arvinas approaches late-stage development. The company is dedicated to creating therapies targeting disease-causing proteins, with ongoing clinical programs for prostate and breast cancer treatments.
Arvinas, Inc. (Nasdaq: ARVN) announced the appointment of Lisa Sinclair as Senior Vice President of Corporate Operations. With over 25 years in the biopharmaceutical industry, Sinclair previously held key roles at Rallybio and AstraZeneca. Arvinas CEO John Houston emphasized her strategic operational experience as crucial for the company's planned entry into pivotal clinical trials by year-end. Arvinas is focused on developing therapies that degrade disease-causing proteins using its proprietary PROTAC® platform, aiming to enhance the lives of patients with serious diseases.
Arvinas, Inc. (Nasdaq: ARVN) reported its Q2 2022 financial results, highlighting revenues of $31.3 million, a significant increase from $5.5 million in Q2 2021. The net loss rose to $70.0 million from $50.3 million, attributed to higher R&D and administrative costs. The company plans to initiate pivotal trials for ARV-471 and bavdegalutamide in metastatic cancers, with the Phase 3 trial set for 2H 2023. As of June 30, 2022, cash and equivalents were $1,347.7 million, sufficient to fund operations beyond 2024.
Arvinas, Inc. (Nasdaq: ARVN) has appointed John Northcott as the Chief Commercial Officer (CCO), a new role in the company. Northcott brings extensive experience from notable companies like Nektar Therapeutics and Pharmacyclics, where he successfully led product development and commercialization. CEO John Houston expressed confidence that Northcott's expertise will significantly aid in advancing Arvinas' drug pipeline, especially as the company prepares for late-stage development. Arvinas specializes in therapies that target and degrade disease-causing proteins, aiming to improve outcomes in cancer treatments.
Arvinas, a clinical-stage biotechnology firm listed on Nasdaq under the symbol ARVN, announced its participation in the Goldman Sachs 43rd Annual Global Healthcare Conference scheduled for June 13 at 4:20 p.m. ET. The event will feature a fireside chat with the company's management in Rancho Palos Verdes, California. A live audio webcast will be available on the company's website. Arvinas focuses on developing therapies that degrade disease-causing proteins, utilizing its proprietary PROTAC® technology, with ongoing clinical programs targeting prostate and breast cancer.